Genprex's Gene Therapy GPX-002 Rejuvenates Beta Cells In Type 2 Diabetic Animal Studies. Additionally, PGP-011, RJVA-001, harmine, and RenBio's gene therapy are also highly groundbreaking.

https://www.nasdaq.com/articles/genprexs-gene-therapy-gpx-002-rejuvenates-beta-cells-type-2-diabetic-animal-studies

Genprex Inc. (GNPX) reported positive preliminary preclinical results for its diabetes gene-therapy candidate GPX-002, showing in-vivo proof-of-concept in both Type 2 diabetic non-human primates and mice.

The company says the findings support the potential of GPX-002 to restore insulin-producing function by rejuvenating exhausted beta cells.

Additionally, PGP-011, RJVA-001, harmine, and RenBio's gene therapy are also highly groundbreaking.